1. "Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. (6th November 2014) Authors: Champion, Brian R; Kodialbail, Prithvi; Illingworth, Sam; Rasiah, Nalini; Cochrane, Dan; Beadle, John; Fisher, Kerry; Brown, Alice CN Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. "First AID" for T cell adoptive transfer: TCR affinity maturation by somatic hypermutation. (7th November 2013) Authors: Gozlan, Yosi M; Tzehoval, Esther; Eisenbach, Lea Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies. Issue 2 (15th February 2021) Authors: Sinha, Debottam; Srihari, Sriganesh; Beckett, Kirrliee; Le Texier, Laetitia; Solomon, Matthew; Panikkar, Archana; Ambalathingal, George R; Lekieffre, Lea; Crooks, Pauline; Rehan, Sweera; Neller, Michelle A.; Smith, Corey; Khanna, Rajiv Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 03.05 Towards a B cell vaccine for tumour expressed self-antigens. (21st September 2022) Authors: Escobar-Riquelme, FN; Price, M; Kansakar, S; Toellner, KM; Zhang, Y Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 03.06 Understanding how epitope binding influences antibody dependent complement engagement for therapy of B-cell malignancies. (21st September 2022) Authors: Bondza, S; Buijs, J; Lux, A Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 06.03 Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. (21st September 2022) Authors: Wienke, J; Visser, LL; Kholosy, WM; Keller, KM; Barisa, M; Munnings-Tomes, S; Carlton, E; Poon, E; Rodriguez, A; Bernardi, R; van den Ham, F; van Hooff, SR; Langenberg, KPS; Holstege, FCP; Chesler, L; Anderson, J; Caron, HN; Margaritis, T; van Noesel, MM; Molenaar, JJ Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 06.04 Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. (21st September 2022) Authors: Pan, C; Zhu, Z; Zhu, S; Ma, A; Chittepu, VCSR; Farrukh, H; Cheng, F Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 08.03 MHJC-based large-scale screening of anti-tumor T cells in chronic lymphocytic leukemia reveals CD8+ T cells with specificity against the clonotypic B-cell receptor immunoglobulin. (21st September 2022) Authors: Basavaraju, Y; Vardi, A; Agathangelidis, A; Pedersen, NW; Karypidou, M; Schaap-Johansen, A; Fylaktou, A; Stavroyianni, N; Iskas, M; Anagnostopoulos, A; Chatzidimitriou, A; Marcatili, P; Hadrup, SR; Stamatopoulos, K Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b receptor (DNR) to enable efficacy in solid tumor models. (21st September 2022) Authors: Strzalkowski, TJ; Cadilha, BL; Dalloul, I; Manske, K; Endres, S; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma. (21st September 2022) Authors: Benmebarek, M; Märkl, F; Keyl, J; Cadilha, B; Geiger, M; Karches, C; Obeck, H; Schwerdtfeger, M; Briukhovetska, D; Jobst, J; Müller, PJ; Seifert, M; Grünmeier, R; Thomas, M; Marr, C; Levesque, M; Heppt, M; Endres, S; Klein, C; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗